MedTrace Logo

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

NCT05322499 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-04-11

No results posted yet for this study

Summary

To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy

Conditions

  • Stage IV Esophagus Squamous Cell Carcinoma

Interventions

DRUG

Camrelizumab

200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);

DRUG

Irinotecan

100-125mg/m2，d1，d8；q21d

DRUG

Paclitaxel

135-175mg/m2，d1，Q3W

DRUG

Paclitaxel-albumin

100-135mg/m2, d1、d8，Q3W

DRUG

Docetaxel

60-75mg/m2，d1，Q3W

DRUG

Anlotinib

12mg，qd，d1-d14，q3w

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Xinmin Yu, Doctor · Zhejiang Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2023-04-15
Completion
2025-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322499 on ClinicalTrials.gov